Bipolar Disorder"Costs and Comorbidity

Published Online: June 15, 2005
Robert M.A. Hirschfeld, MD; and Lana A. Vornik, MSc

Not only is bipolar disorder a chronic, severe psychiatric disorder, it is also expensive to treat and expensive to society. An estimate of the total cost of bipolar disorder made more than a decade ago was as high as $45 billion per year. Most of this cost is accounted for by indirect costs related to reduced functional capacity and lost work. Patients with bipolar disorder have higher rates of utilization of healthcare resources compared with the general population and compared with patients with other types of psychiatric conditions. Comorbidity contributes to the heavy burden that bipolar disorder imposes on society. Bipolar disorder frequently occurs together with other psychiatric disorders, especially anxiety disorders and substance abuse. In addition, bipolar disorder has been associated with a variety of general medical conditions, which further complicate management of the psychiatric disorder.

(Am J Manag Care. 2005;11:S85-S90)

Cost of Bipolar Disorder

Bipolar disorder is a recurrent and sometimes chronic psychiatric illness, which is characterized by episodes of mania or hypomania and depression. Bipolar disorder causes a significant impact on the patient's quality of life, as well as a considerable economic burden on both the individual and society as a whole. According to the World Health Organization report, bipolar disorder is ranked sixth in the top 10 causes of disability worldwide in the 15-to 44-year age group. Moreover, bipolar disorder is ranked third among mental illnesses after unipolar major depression and schizophrenia as the source of disease burden in established market economies.1

Until recently, much of the research in bipolar disorder has focused on bipolar I disorder, with a lifetime prevalence of about 1% in the general population.2-4 However, since epidemiologic studies started to use a broader definition of bipolar disorder, comprising a wider range of illnesses than pure mania, including hypomania, recurrent brief hypomania, sporadic brief hypomania, and cyclothymia,5,6 the lifetime prevalence estimates of bipolar spectrum disorder are now placed at at least 5% of the general population, 7 with some authors producing even higher estimates.8 In view of the high prevalence of bipolar spectrum disorder, it is important to assess the associated costs to society and to the afflicted individual.

Direct and Indirect Costs of Bipolar Disorder. Cost-of-illness studies typically assess direct and indirect costs of a particular disorder. Direct costs include direct medical expenditures, including cost of hospitalization, emergency department services, psychiatric visits, the cost of medications, and others. Indirect costs of illness assess the level of impairment, and the effect of the disorder on work productivity, as well as social welfare costs and criminal justice costs.9

The total economic burden of bipolar disorder in the United States was $45 billion in 1991. Of that total, $7 billion was a result of direct costs of inpatient and outpatient care, as well as nontreatment-related expenditures, such as costs of criminal justice. Indirect costs were estimated at $38 billion and included the lost productivity of the patients and their caregivers. The lost productivity of patients who have committed suicide alone was assessed at $8 billion.10

One key aspect of cost to society is the impact of bipolar disorder in the workplace. The recently completed National Comorbidity Replication study is a nationally representative survey of mental disorders among US residents aged 18 and older.11 Bipolar disorder was associated with 49.5 annual lost workdays per ill worker. Major depressive disorder (MDD) was associated with 31.9 annual lost workdays per ill worker. Projected losses for the total US labor force yielded an estimate of 180 million lost workdays per year and $25.9 billion salary-equivalent lost productivity per year associated with bipolar disorder compared with 116.1 million workdays and $19.4 billion salary-equivalent lost productivity per year associated with MDD.12

Many aspects of patients' lives are affected by their bipolar disorder, leading to an increase in the indirect costs of the disorder. Bipolar disorder is frequently associated with family discord, problems with the justice system, and workplace problems. One study has shown that only 50% of bipolar patients were employed 6 months after discharge from a psychiatric hospitalization. These findings have been corroborated (R. C. Kessler, MD, unpublished, 2005).

Cost of Misdiagnosis. Failure to recognize bipolar disorder in the early stages of the disease is also associated with increased costs. In fact, as many as 70% of patients who seek professional services are initially misdiagnosed, the most frequent misdiagnosis being unipolar depression.13 The correct diagnosis of bipolar disorder is complicated by the fact that a majority of patients present to the physician while depressed. Misdiagnosis of bipolar disorder as unipolar depression can have significant economic consequences. The cost of bipolar disorder misdiagnosis was addressed in a study of paid claims of 3349 California Medicaid patients with bipolar disorder.14 Of these patients, only 42% used a mood stabilizer during the first posttreatment year, and only 5.5% of patients used a mood stabilizer consistently for 1 year. Direct healthcare costs were significantly higher among the patients who failed to receive a mood stabilizer. Specifically, mood stabilizer treatment was associated with a decrease in the total cost of treatment of $5044 per year, primarily because of the reductions in ambulatory costs and costs of hospitalizations.14

Psychiatric Comorbidities of Bipolar Disorder

Psychiatric comorbidity, defined as the presence of a concurrent psychiatric syndrome in addition to the principal diagnosis, is common in psychotic and major affective disorders.15 Epidemiologic studies have shown that between 25% and 50% of people with 1 mental disorder have at least 1 cooccurring mental disorder. High rates of comorbidity contribute to the cost of treatment of patients with psychiatric disorders, as comorbidity hinders diagnosis and complicates treatment.

Psychiatric and general medical comorbidity are especially common in patients with bipolar disorder.16 The commonly reported rates of lifetime comorbidity in bipolar I samples are higher than 50%, and some authors report rates as high as 70%.17 The rates of comorbidity are assessed in 2 types of studies: epidemiologic studies and general community, and clinical samples studies.

Community Studies. The Epidemiologic Catchment Area (ECA) study was a collaborative research effort conducted by the National Institute of Mental Health, which assessed the prevalence of psychiatric disorders in the combined community and institutional populations. The lifetime prevalence of any affective disorder was reported at 8.3%, and the lifetime prevalence of any bipolar disorder at 1.3% (0.8% for bipolar I and 0.5% for bipolar II). The ECA study further assessed the comorbidity of bipolar disorder with any substance abuse (ie, drug and alcohol), panic disorder, and obsessive-compulsive disorder (OCD). The ECA identified 168 individuals with bipolar disorder. Among them, 46% had comorbid alcohol abuse or dependence, 41% had drug abuse or dependence, 21% had panic disorder, and 21% had OCD.18-20

Strikingly high rates of comorbidity in patients with bipolar disorder were reported in the National Comorbidity Survey (NCS) study, a general population survey of Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised (DSMIII-R) disorders, conducted 1 decade after the ECA study. The lifetime prevalence rates of bipolar disorder in the NCS study were lower than commonly reported, with the rate for manic episodes reported at 1.6% and dysthymia at 6.4%.2 The lifetime prevalence of bipolar I disorder (euphoric-grandiose bipolar disorder, characterized by euphoria, grandiosity, and decreased need for sleep) was 0.45%.21 Comorbidity rates of bipolar I disorder with other lifetime DSM-III-R disorders were further evaluated in a small clinical reappraisal study of 59 respondents of the NCS.22 Twenty-nine manic patients with euphoria, grandiosity, and the ability to maintain energy without sleep were analyzed. All cases reported at least 1 other DSM-III-R disorder, and 95.5% of cases met criteria for 3 or more disorders. The episode of bipolar disorder (either mania or depression) for 59.3% occurred at a later age than at least 1 other NCS/DSM-III-R disorder.21

Clinical Studies. Bipolar disorder comorbidity with other mental disorders has also been evaluated in a number of clinic-based studies. A study from the Stanley Foundation Bipolar Treatment Outcome Network evaluated axis I psychiatric comorbidity in 288 patients with bipolar I and II disorder. The evaluation showed that 65% of the patients with bipolar disorder met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSMIV) criteria for at least 1 other lifetime axis I disorder. Lifetime and current axis I comorbidity were associated with earlier onset of affective symptoms and syndromal bipolar disorder.22

Forty-one patients admitted for a first psychiatric hospitalization were assessed for the presence of psychiatric and general medical comorbidities in a study conducted by Strakowski and colleagues.23 Of these patients, comorbidities were found in 51% of patients, including 39% of psychiatric comorbidities and 22% of general medical comorbidities. More than 1 comorbid condition was found in 22% of the subjects. Women had a 2.7-fold higher rate of comorbidities than men; 56% of women admitted for mania had a comorbid psychiatric disorder compared with 12.5% of men.23 Other studies specifically address bipolar disorder comorbidities with specific other psychiatric disorders and will be discussed later.

Substance and Alcohol Abuse

PDF is available on the last page.
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Hematology Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Pain Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST